Supernus Pharmaceuticals Initiates Phase IIa Clinical Trial for SPN810 in Conduct Disorder

ROCKVILLE, Md.--(BUSINESS WIRE)--Supernus Pharmaceuticals, Inc. today announced the initiation of a Phase IIa U.S. clinical trial of its product candidate SPN810 in the treatment of serious conduct problems in the setting of ADHD. The trial is a proof-of-concept, open-label study with pediatric subjects randomized according to weight group and titrated to receive one of four doses over a six-week treatment period. The primary objective is to measure safety and tolerability, with a secondary measure of efficacy in reducing symptoms of serious conduct problems.